Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8416 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KMT2APARP10KAT6APOLB | |
| SCHEMBL9945960 | 0.89 | ALDH1A1 (0.42) | ALDH1A1KMT2APARP10KAT6APOLB | |
| SCHEMBL29955317 | 0.85 | ALOX15 (0.40) | ALDH1A1KMT2APOLB | |
| SCHEMBL29636290 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KMT2APARP10KAT6APOLB | |
| SCHEMBL20659060 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KMT2APARP10KAT6APOLB | |
| SCHEMBL29454619 | 0.79 | CA1 (0.48) | — | |
| SCHEMBL931782 | 0.79 | CA1 (0.48) | — | |
| SCHEMBL1020456 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KMT2APARP10KAT6APOLB | |
| SCHEMBL30829775 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KMT2APARP10KAT6APOLB | |
| SCHEMBL17592670 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KMT2APARP10POLBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | ALDH1A1 131/4885KMT2A 530/4885PARP10 583/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | ALDH1A1 4740/4885KMT2A 2422/4885PARP10 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.